Pharma Equity Group A/S Cl A Net Assets
Pharma Equity Group A/S Cl A net assets. Based on the latest financial reports, Pharma Equity Group A/S Cl A (PEG) has net assets worth Dkr25.47 Million DKK (≈ $3.99 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Dkr38.90 Million ≈ $6.09 Million USD) and total liabilities (Dkr13.43 Million ≈ $2.10 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Pharma Equity Group A/S Cl A net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Dkr25.47 Million |
| % of Total Assets | 65.48% |
| Annual Growth Rate | -4.55% |
| 5-Year Change | -40.16% |
| 10-Year Change | -73.68% |
| Growth Volatility | 100.34 |
Net Assets of Pharma Equity Group A/S Cl A (2008–2025)
Net assets of Pharma Equity Group A/S Cl A from 2008 to 2025. This chart illustrates how Pharma Equity Group A/S Cl A's net assets have evolved over time, based on quarterly financial data. See net asset quality index of Pharma Equity Group A/S Cl A to measure how much of total assets are equity-financed.
Annual Net Assets for Pharma Equity Group A/S Cl A (2008–2025)
The table below shows the annual net assets of Pharma Equity Group A/S Cl A from 2008 to 2025. For live market cap and overall valuation, see Pharma Equity Group A/S Cl A (PEG) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | Dkr25.47 Million ≈ $3.99 Million |
-47.88% |
| 2024-09-30 | Dkr48.88 Million ≈ $7.65 Million |
+92.93% |
| 2023-09-30 | Dkr25.33 Million ≈ $3.96 Million |
-44.98% |
| 2022-09-30 | Dkr46.05 Million ≈ $7.20 Million |
+8.17% |
| 2021-09-30 | Dkr42.57 Million ≈ $6.66 Million |
+24.17% |
| 2020-09-30 | Dkr34.28 Million ≈ $5.36 Million |
-48.95% |
| 2019-09-30 | Dkr67.16 Million ≈ $10.51 Million |
-13.43% |
| 2018-09-30 | Dkr77.57 Million ≈ $12.14 Million |
-8.84% |
| 2017-09-30 | Dkr85.09 Million ≈ $13.31 Million |
-12.08% |
| 2016-09-30 | Dkr96.78 Million ≈ $15.14 Million |
-2.77% |
| 2015-09-30 | Dkr99.53 Million ≈ $15.57 Million |
+1.62% |
| 2014-09-30 | Dkr97.95 Million ≈ $15.32 Million |
+192.90% |
| 2013-09-30 | Dkr-105.44 Million ≈ $-16.50 Million |
-389.77% |
| 2012-09-30 | Dkr36.39 Million ≈ $5.69 Million |
-54.33% |
| 2011-09-30 | Dkr79.67 Million ≈ $12.46 Million |
+50.13% |
| 2010-09-30 | Dkr53.06 Million ≈ $8.30 Million |
-0.76% |
| 2009-09-30 | Dkr53.47 Million ≈ $8.37 Million |
-4.95% |
| 2008-09-30 | Dkr56.25 Million ≈ $8.80 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Pharma Equity Group A/S Cl A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6657900000.0% over the analyzed period, indicating profitable operations and earnings retention.
Pharma Equity Group A/S Cl A Net Assets Breakdown (September 2025)
Pharma Equity Group A/S Cl A net assets breakdown by equity component as of September 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Dkr122.76 Million | 481.93% |
| Other Comprehensive Income | Dkr-97.28 Million | -381.93% |
| Total Equity | Dkr25.47 Million | 100.00% |
Pharma Equity Group A/S Cl A Competitors by Market Cap
The table below lists competitors of Pharma Equity Group A/S Cl A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KR Motors Co. Ltd.
KO:000040
|
$13.60 Million |
|
Vinpai SAS
PA:ALVIN
|
$13.60 Million |
|
IDT Australia Ltd
AU:IDT
|
$13.61 Million |
|
FIPP S.A.
PA:FIPP
|
$13.61 Million |
|
Foxx Development Holdings Inc.
NASDAQ:FOXX
|
$13.59 Million |
|
Aguia Resources Ltd
AU:AGR
|
$13.59 Million |
|
Pegasus Heights Bhd
KLSE:4464
|
$13.58 Million |
|
Excel Realty N Infra Limited
NSE:EXCEL
|
$13.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pharma Equity Group A/S Cl A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 48,875,000 to 25,472,000, a change of -23,403,000 (-47.9%).
- Net loss of 25,382,000 reduced equity.
- Other comprehensive income decreased equity by 97,284,000.
- Other factors increased equity by 99,263,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Dkr-25.38 Million | -99.65% |
| Other Comprehensive Income | Dkr-97.28 Million | -381.93% |
| Other Changes | Dkr99.26 Million | +389.69% |
| Total Change | Dkr- | -47.88% |
Book Value vs Market Value Analysis
This analysis compares Pharma Equity Group A/S Cl A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.41x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.00x to 3.41x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-09-30 | Dkr66.77 | Dkr0.07 | x |
| 2009-09-30 | Dkr55.03 | Dkr0.07 | x |
| 2010-09-30 | Dkr60.03 | Dkr0.07 | x |
| 2011-09-30 | Dkr46.29 | Dkr0.07 | x |
| 2012-09-30 | Dkr20.64 | Dkr0.07 | x |
| 2013-09-30 | Dkr-69.55 | Dkr0.07 | x |
| 2014-09-30 | Dkr49.41 | Dkr0.07 | x |
| 2015-09-30 | Dkr4.37 | Dkr0.07 | x |
| 2016-09-30 | Dkr4.98 | Dkr0.07 | x |
| 2017-09-30 | Dkr3.83 | Dkr0.07 | x |
| 2018-09-30 | Dkr3.26 | Dkr0.07 | x |
| 2019-09-30 | Dkr0.33 | Dkr0.07 | x |
| 2020-09-30 | Dkr1.08 | Dkr0.07 | x |
| 2021-09-30 | Dkr0.77 | Dkr0.07 | x |
| 2022-09-30 | Dkr1.04 | Dkr0.07 | x |
| 2023-09-30 | Dkr0.02 | Dkr0.07 | x |
| 2024-09-30 | Dkr0.05 | Dkr0.07 | x |
| 2025-09-30 | Dkr0.02 | Dkr0.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pharma Equity Group A/S Cl A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -99.65%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.53x
- Recent ROE (-99.65%) is below the historical average (-38.73%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -164.74% | 0.00% | 0.00x | 4.65x | Dkr-98.29 Million |
| 2009 | -25.74% | 0.00% | 0.00x | 1.62x | Dkr-16.71 Million |
| 2010 | -2.67% | -273.69% | 0.00x | 9.37x | Dkr-6.72 Million |
| 2011 | -21.31% | -109.63% | 0.03x | 6.37x | Dkr-24.94 Million |
| 2012 | -118.94% | -326.58% | 0.03x | 13.85x | Dkr-46.92 Million |
| 2013 | 0.00% | -287.29% | 0.20x | 0.00x | Dkr-131.28 Million |
| 2014 | -6.07% | -4492.42% | 0.00x | 1.27x | Dkr-15.70 Million |
| 2015 | -2.92% | -447.26% | 0.00x | 1.33x | Dkr-12.26 Million |
| 2016 | -1.11% | -98.20% | 0.01x | 1.35x | Dkr-10.35 Million |
| 2017 | 0.21% | 0.00% | 0.00x | 1.01x | Dkr-8.33 Million |
| 2018 | -9.94% | 0.00% | 0.00x | 1.04x | Dkr-15.47 Million |
| 2019 | -21.47% | 0.00% | 0.00x | 1.20x | Dkr-21.13 Million |
| 2020 | -95.90% | 0.00% | 0.00x | 1.68x | Dkr-36.30 Million |
| 2021 | 12.67% | 0.00% | 0.00x | 1.50x | Dkr1.14 Million |
| 2022 | 7.56% | 0.00% | 0.00x | 1.54x | Dkr-1.13 Million |
| 2023 | -97.14% | 0.00% | 0.00x | 2.67x | Dkr-27.14 Million |
| 2024 | -49.97% | 0.00% | 0.00x | 1.34x | Dkr-29.31 Million |
| 2025 | -99.65% | 0.00% | 0.00x | 1.53x | Dkr-27.93 Million |
Industry Comparison
This section compares Pharma Equity Group A/S Cl A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,818,293,200
- Average return on equity (ROE) among peers: 4.71%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pharma Equity Group A/S Cl A (PEG) | Dkr25.47 Million | -164.74% | 0.53x | $13.60 Million |
| ALK-Abelló A/S (ALK-B) | $6.21 Billion | 69.30% | 0.11x | $7.77 Billion |
| Bavarian Nordic (BAVA) | $999.68 Million | -24.01% | 0.54x | $2.93 Billion |
| Genmab A/S (GMAB) | $1.18 Billion | 31.56% | 0.08x | $35.84 Billion |
| Gubra A/S (GUBRA) | $450.57 Million | -8.10% | 0.36x | $766.63 Million |
| Zealand Pharma A/S (ZEAL) | $252.23 Million | -45.18% | 1.52x | $2.58 Billion |
About Pharma Equity Group A/S Cl A
Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which the current therapy is lacking or in need of improvement. Its products under development, includes RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment… Read more